Dennis J Slamon Selected Research

palbociclib

1/2022	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
1/2021	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
11/2020	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
9/2020	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
1/2020	Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
1/2020	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer.
1/2019	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
11/2018	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
11/2018	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
11/2016	Palbociclib and Letrozole in Advanced Breast Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dennis J Slamon Research Topics

Disease

79	Breast Neoplasms (Breast Cancer) 01/2022 - 02/2002
71	Neoplasms (Cancer) 01/2022 - 03/2002
14	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2003
7	Neutropenia 09/2020 - 04/2002
7	Disease Progression 01/2020 - 03/2004
7	Neoplasm Metastasis (Metastasis) 01/2018 - 03/2002
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 07/2010
4	Retinoblastoma (Glioblastoma, Retinal) 08/2013 - 03/2002
3	Fatigue 11/2016 - 07/2002
3	Stomach Neoplasms (Stomach Cancer) 08/2015 - 03/2010
3	Lung Neoplasms (Lung Cancer) 12/2010 - 06/2002
2	Cardiotoxicity 01/2022 - 01/2014
2	Ovarian Epithelial Carcinoma 01/2021 - 06/2008
2	Leukopenia 01/2018 - 11/2016
2	Melanoma (Melanoma, Malignant) 08/2015 - 08/2010
2	Renal Cell Carcinoma (Grawitz Tumor) 08/2013 - 01/2012
2	Exanthema (Rash) 02/2009 - 02/2007
2	Diarrhea 02/2009 - 02/2007
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2021
1	Residual Neoplasm 01/2021
1	Pathologic Complete Response 01/2020
1	Toxic Optic Neuropathy 01/2019
1	Polyploidy 01/2019
1	Infections 01/2019

Drug/Important Bio-Agent (IBA)

32	Trastuzumab (Herceptin)FDA Link 01/2022 - 02/2002
20	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2002
16	palbociclibIBA 01/2022 - 01/2009
15	Hormones (Hormone)IBA 01/2022 - 01/2003
14	ErbB Receptors (EGF Receptor)IBA 01/2022 - 12/2003
11	Estrogen ReceptorsIBA 01/2022 - 01/2009
9	Fulvestrant (Faslodex)FDA Link 01/2022 - 03/2013
9	Lapatinib (GW572016)FDA Link 01/2021 - 02/2006
8	Phosphotransferases (Kinase)IBA 01/2019 - 01/2003
8	DNA (Deoxyribonucleic Acid)IBA 08/2015 - 01/2005
7	Cyclin-Dependent Kinase 4IBA 01/2021 - 08/2013
7	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2008
7	Phenobarbital (Luminal)FDA Link 11/2020 - 01/2005
7	Biological ProductsIBA 01/2020 - 02/2006
7	Docetaxel (Taxotere)FDA Link 01/2014 - 05/2004
6	AnthracyclinesIBA 01/2022 - 05/2007
6	Letrozole (Femara)FDA LinkGeneric 09/2020 - 01/2015
6	human ERBB2 proteinIBA 01/2020 - 04/2006
5	Messenger RNA (mRNA)IBA 01/2021 - 02/2008
5	RNA (Ribonucleic Acid)IBA 02/2015 - 06/2008
5	PlatinumIBA 06/2014 - 05/2004
4	Pharmaceutical PreparationsIBA 01/2021 - 05/2004
4	InterferonsIBA 01/2017 - 02/2014
4	Cyclin-Dependent Kinases (cdk Proteins)IBA 02/2016 - 08/2013
4	Bevacizumab (Avastin)FDA Link 06/2015 - 08/2010
4	Paclitaxel (Taxol)FDA LinkGeneric 06/2015 - 08/2004
4	Carboplatin (JM8)FDA LinkGeneric 06/2014 - 05/2004
3	taxaneIBA 10/2021 - 08/2004
3	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2020 - 03/2013
3	Peptides (Polypeptides)IBA 01/2020 - 09/2005
3	SteroidsIBA 01/2020 - 01/2003
3	ribociclibIBA 01/2020 - 01/2018
3	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 01/2019 - 04/2013
3	Epidermal Growth Factor (EGF)IBA 01/2018 - 12/2004
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 02/2009
3	MethyltransferasesIBA 08/2015 - 02/2010
3	Cisplatin (Platino)FDA LinkGeneric 06/2014 - 05/2004
3	Monoclonal AntibodiesIBA 08/2011 - 01/2003
2	abemaciclibIBA 01/2020 - 01/2018
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 06/2011
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2019 - 06/2013
2	2- (3- (4- ((2,6- dimethylmorpholino)methyl)styryl)- 1H- indazol- 6- yl)- 5'- methoxyspiro(cyclopropane- 1,3'- indolin)- 2'- oneIBA 01/2019 - 01/2019
2	Everolimus FDA Link 01/2018 - 02/2015
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 07/2010
2	UbiquitinIBA 01/2017 - 08/2015
2	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2017 - 08/2015
2	CyclinsIBA 02/2016 - 03/2002
2	Tamoxifen FDA LinkGeneric 02/2015 - 04/2006
2	Cyclin D1IBA 01/2015 - 03/2002
2	Transcription Factors (Transcription Factor)IBA 06/2014 - 04/2010
2	Tyrosine Kinase InhibitorsIBA 06/2013 - 02/2007
2	Dasatinib (BMS 354825)FDA Link 05/2013 - 11/2007
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2012 - 03/2004
2	PeriostinIBA 08/2011 - 11/2010
2	EnzymesIBA 03/2011 - 01/2003
2	hydrogen sulfite (bisulfite)IBA 02/2010 - 08/2005
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2006 - 08/2004
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2005 - 01/2003
2	Complementary DNA (cDNA)IBA 01/2003 - 06/2002
1	Oncogene Proteins (Oncogene Protein)IBA 01/2022
1	Codon (Codons)IBA 01/2022
1	tucatinibIBA 01/2022
1	Taxoids (Taxanes)IBA 10/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	AntioxidantsIBA 01/2021
1	AlpelisibIBA 01/2020
1	Anastrozole (Arimidex)FDA LinkGeneric 01/2020
1	Pemetrexed (MTA)FDA Link 01/2019
1	Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)IBA 01/2019
1	navitoclaxIBA 01/2019

Therapy/Procedure

48	Therapeutics 01/2022 - 01/2003
19	Drug Therapy (Chemotherapy) 01/2022 - 07/2002
5	Adjuvant Chemotherapy 06/2019 - 03/2006
2	Immunotherapy 01/2021 - 01/2015
1	Neoadjuvant Therapy 01/2021